Subjects and research methods: The study was designed as an uncontrolled clinically interventional study on primary HCC patients taken pembrolizumab in second-line treatment at Hanoi Oncology Hospital (HOH) and Vietnam National Cancer Hospital from January 1, 2020 to June 30, 2022.